pharma · ADHD · Idiopathic Hypersomnia · ZVRA
ZEVRA THERAPEUTICS
ZEVRA THERAPEUTICS, INC.
ZEVRA THERAPEUTICS is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker ZVRA. Primary therapeutic focus areas include ADHD, Idiopathic Hypersomnia, Combined D,L-2-hydroxyglutaric Aciduria
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2006
- Employees
- 81
- Programs
- 4
- Drugs
- 6
- Patents
- 5
Sodium phenylbutyrate
Phase 2 · small molecule · Medium-chain Acyl-CoA Dehydrogenase Deficiency
Sodium phenylbutyrate for Medium-chain Acyl-CoA Dehydrogenase Deficiency is a Phase 2 program (small_molecule) at ZEVRA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code STUDY24100064
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ZEVRA THERAPEUTICS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Medium-chain Acyl-CoA Dehydrogenase Deficiency
- Status
- active
- Trials
- 1